The biology of VEGF and its receptors
The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Ferrara et al., 2003
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“VEGF induces a potent angiogenic response in a variety of in vivo model”
BackgroundSelf-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Self-citationMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 1×
“VEGF is known also as vascular permeability factor, based on its ability to induce vascular leakag”
BackgroundFailure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Self-citationVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Many molecules have been implicated as positive regulators of angiogenesis, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-α, TGF-β, hepatocyte growth factor (HGF, or scatter factor), tumor necrosis factor-α, angiogenin, interleukin (IL)-8 and the angiopoietin”
Background
Research works printed but not linked: 3
- Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
- Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press).
Cited by
Items 901–1,000 of 1,056
Kugeratski, F. G., Atkinson, S. J., Neilson, L. J., Lilla, S., Knight, J. R. P., Serneels, J., Juin, A., Ismail, S., Bryant, D. M., Markert, E. K., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aan8247 · Cited by 125
Osteogenesis and bone remodeling: A focus on growth factors and bioactive peptides
Toosi, S. H., & Behravan, J. (2019) · BioFactors · doi:10.1002/biof.1598 · Cited by 143
“VEGFs comprise of six members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental GF.(73,75) VEGFs are signal peptides involved in vasculogenesis and angiogenesis.”
BackgroundInfluentialRegulation of Uterine Spiral Artery Remodeling: a Review
Albrecht, E. D., & Pepe, G. J. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00212-8 · Cited by 132
Uemura, A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25964 · Cited by 128
“Under hypoxic conditions, activated HIFs transcriptionally upregulate expression levels of a series of proangiogenic genes, including VEGF (7–9).”
Herrmann, J., Lerman, L. O., Mukhopadhyay, D., Napoli, C., & Lerman, A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000233387.90257.9b · Cited by 142
Recent advances in the pathobiology and management of Kasabach–Merritt phenomenon
O’Rafferty, C., O’Regan, G. M., Irvine, A. D., & Smith, O. P. (2015) · British Journal of Haematology · doi:10.1111/bjh.13557 · Cited by 130
“…(TGFA), epidermal growth factor (EGF), transforming growth factor beta (TGFB1), insulin-like growth factor 1 (IGF1), fibroblast growth factor (FGF), keratinocyte growth factor (KGF), and can also be upregulated by cytokines such as interleukins 1 alpha and 6 (IL1A and IL6) (Ferrara et al, 2003).”
BackgroundPark, H., Lim, M., Jung, H., Lee, S., Paik, K., & Chang, M. (2010) · Glia · doi:10.1002/glia.20992 · Cited by 136
“for VEGF, VEGFR1 (Flt-1), and VEGFR2 (KDR/Flk-1) (Ferrara et al., 2003).”
BackgroundLieu, C. H., Tran, H., Jiang, Z.-Q., Mao, M., Overman, M. J., Lin, E., Eng, C., Morris, J., Ellis, L., Heymach, J. V., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077117 · Cited by 127
“These ligands are associated with resistance to bevacizumab-containing chemotherapy in mCRC, but causation remains to be established.”
InfluentialApelin signaling drives vascular endothelial cells toward a pro-angiogenic state
Helker, C. S., Eberlein, J., Wilhelm, K., Sugino, T., Malchow, J., Schuermann, A., Baumeister, S., Kwon, H.-B., Maischein, H.-M., Potente, M., et al. (2020) · eLife · doi:10.7554/elife.55589 · Cited by 129
Age‐Related Macular Degeneration
Cheung, L. K., & Eaton, A. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1264 · Cited by 120
“The VEGF family consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor, with VEGF-A as the key regulator of both physiologic and pathologic angiogenesis.(43) Thus, VEGF-A has been the target of most anti-VEGF treatments.”
BackgroundPfander, D., Kobayashi, T., Knight, M. C., Zelzer, E., Chan, D. A., Olsen, B. R., Giaccia, A. J., Johnson, R. S., Haase, V. H., & Schipani, E. (2004) · Development · doi:10.1242/dev.01138 · Cited by 128
“An understanding of this process at the molecular level is emerging (Kronenberg, 2003; Ferrara et al., 2003; Ortega et al., 2003; Olsen et al., 2000; Karsenty, 1999; Harper and Klagsbrun, 1999; Erlebacher et al., 1995).”
Backgrounddel Moral, P.-M., Sala, F. G., Tefft, D., Shi, W., Keshet, E., Bellusci, S., & Warburton, D. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2005.11.022 · Cited by 128
“Moreover, the Vascular Endothelial Growth factor (VEGF) family of ligands and their cognate receptors FMS-like tyrosine kinase 1 (Flt-1) or VEGFR1, and Fetal Liver Kinase-1 (Flk-1) or VEGF-R2, affect a wide variety of physiological and pathological events (Ferrara et al., 2003).”
BackgroundFlorio, T. (2007) · Frontiers in bioscience · doi:10.2741/2722 · Cited by 128
“These cells, infiltrating the peritumoral area in response to VEGF (192), produce pro-survival and pro-angiogenic factors resulting in the activation of endothelial cells and the induction of neo-vascularization.”
BackgroundSpuch, C., Antequera, D., Portero, A., Orive, G., Hernández, R. M., Molina, J. A., Bermejo‐Pareja, F., Pedraz, J. L., & Carro, E. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.03.042 · Cited by 136
“First, we confirmed that this experimental approach leads to an efficient formation of new vessels in the cerebral cortex of C57BL/6 mice, agreeing with the angiogenic characteristics of this trophic factor [32].”
Cathepsin B Regulates the Intrinsic Angiogenic Threshold of Endothelial Cells
Im, E., Venkatakrishnan, A., & Kazlauskas, A. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-11-1029 · Cited by 124
“VEGF gene expression is regulated by an oxygen-sensing signaling pathway, which determines the stability of a key transcription factor hypoxia-inducible factor-1 (HIF-1; Ferrara et al., 2003).”
BackgroundPlasmin Modulates Vascular Endothelial Growth Factor-A-Mediated Angiogenesis during Wound Repair
Roth, D., Piekarek, M., Paulsson, M., Christ, H., Bloch, W., Krieg, T., Davidson, J. M., & Eming, S. A. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050372 · Cited by 127
“Moreover, using differential mRNA splicing, the single human VEGF-A gene can give rise to at least eight isoforms (VEGF121, 145, 148, 162, 165, 183, 189, and 206) whose relative levels vary among different tissues.(1,2) The most abundant isoform found in human tissue is VEGF165.”
BackgroundAbdelrahim, M., & Safe, S. H. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.011825 · Cited by 134
“Five members of the VEGF family have been identified (VEGF-A, -B, -C, -D, and -F) and these proteins induce angiogenic responses through binding VEGF receptor-1 (VEGFR-1, or Flk-1), VEGFR-2 (KDR/Flk-1), or VEGFR-3 (Flt-4), which are tyrosine kinases that initiate intracellular kinase signaling pathways (Ferrara et al.…”
BackgroundVEGF causes pulmonary hemorrhage, hemosiderosis, and air space enlargement in neonatal mice
Cras, T. D. L., Spitzmiller, R. E., Albertine, K. H., Greenberg, J. M., Whitsett, J. A., & Akeson, A. L. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00050.2004 · Cited by 127
“VEGF is both a proangiogenic and survival factor for endothelial cells (20, 22, 46).”
BackgroundChang, S.-H., Kanasaki, K., Gocheva, V., Blum, G., Harper, J., Moses, M. A., Shih, S.-C., Nagy, J. A., Joyce, J., Bogyo, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4539 · Cited by 122
Siegle, J., Basin, A., Sastre-Perona, A., Yonekubo, Y., Brown, J. A., Sennett, R., Rendl, M., Tsirigos, A., Carucci, J. A., & Schöber, M. (2014) · Nature Communications · doi:10.1038/ncomms5511 · Cited by 136
“3a, Supplementary Data 1), including the transcription factor Pitx1 and the pro-angiogenic factors Neuropilin (Nrp1, Nrp2) 37 , Secreted Phosphoprotein 1 (Spp1) 38 , Phosphatidylinositol transfer protein cytoplasmic 1 (Pitpnc1) 39 , and Insulin growth factor 2 binding protein 2 (Igf2bp2), as genes with the highest dif…”
Role of angiogenesis on bone formation.
Portal‐Núñez, S., Lozano, D., & Esbrit, P. (2012) · PubMed · doi:10.14670/hh-27.559 · Cited by 147
The role of neovascularisation in the resolution of venous thrombus
Modarai, B., Burnand, K. G., Humphries, J., Waltham, M., & Smith, A. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-09-0596 · Cited by 126
Vascular Proliferation Is Important for Clinical Progress of Endometrial Cancer
Stefansson, I. M., Salvesen, H. B., & Akslen, L. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1163 · Cited by 126
“Among angiogenic factors, VEGF-A is a strong stimulator of endothelial cell proliferation (15) whereas VEGF-C and VEGF-D are considered more important for lymphangiogenesis although their role in various human tumors is not clear (12, 16, 17).”
BackgroundOguro, Y., Miyamoto, N., Okada, K., Takagi, T., Iwata, H., Awazu, Y., Miki, H., Hori, A., Kamiyama, K., & Imamura, S. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.017 · Cited by 126
Goyal, A., Pal, N., Concannon, M., Paul, M., Doran, M., Poluzzi, C., Sekiguchi, K., Whitelock, J. M., Neill, T., & Iozzo, R. V. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.243626 · Cited by 116
Role of MicroRNA in Endothelial Dysfunction and Hypertension
Nemecz, M., Alexandru, N., Tanko, G., & Georgescu, A. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0696-8 · Cited by 130
“Vascular endothelial growth factors (VEGFs), in particular VEGF-A, are implicated in the regulation of the processes required for angiogenesis such as endothelial cell activation, proliferation, migration, and tubule formation [43] .”
BackgroundMicroRNAs in cancer metastasis and angiogenesis
Lou, W., Liu, J., Gao, Y., Zhong, G., Chen, D., Shen, J., Bao, C., Xu, L., Pan, J., Cheng, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23115 · Cited by 129
“AdipoR1, Adiponectin receptor 1 AMD, Age-related macular degeneration AmotL1, Angiomotin-like protein 1 Ang, Angiopoietin BCL9, B-cell CLL/lymphoma 9 C/EBPbeta, CCAAT-enhancer binding protein beta CTGF, Connective tissue growth factor CXCR4, CXC chemokine receptor 4 EMs, Endometriosis Ets1, V-ets erythroblastosis viru…”
BackgroundDifferential activation of vascular genes by hypoxia in primary endothelial cells
Nilsson, I., Shibuya, M., & Wennström, S. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.06.005 · Cited by 132
Developmental and pathological angiogenesis in the central nervous system
Vallon, M., Chang, J., Zhang, H., & Kuo, C. J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1625-0 · Cited by 124
“veGF can be alternatively spliced into several isoforms, with the larger isoforms having large basic domains binding to heparin and proteoglycans found in the extracellular matrix [39].”
Yoo, S., Kwok, S., & Kim, W. (2008) · Mediators of Inflammation · doi:10.1155/2008/129873 · Cited by 126
“RECEPTORS IN RA VEGF165 exerts its biological effects by binding with its receptor subtypes, that is, fms-like tyrosine kinase (Flt-1), kinase insert domain-containing receptor (KDR) and neuropilin-1 (NP-1) [3].”
BackgroundInfluentialBevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer
Krämer, I., & Lipp, H. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00800.x · Cited by 126
“In the absence of VEGF, endothelial cells in immature vessels are unable to survive, causing regression of existing vessels (4).”
BackgroundAmburgey, Ö. A., Chapman, A. C., May, V., Bernstein, I. M., & Cipolla, M. J. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.158931 · Cited by 137
Xiao, Q., Zeng, L., Zhang, Z., Margariti, A., Ali, Z. A., Channon, K. M., Xu, Q., & Hu, Y. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000240251.50215.50 · Cited by 126
Kim, J. G., Chae, Y. S., Sohn, S. K., Cho, Y. Y., Moon, J. H., Park, J. Y., Jeon, S. W., Lee, I. T., Choi, G., & Jun, S. H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1537 · Cited by 126
Bałuk, P., Lee, C. G., Link, H., Ator, E., Haskell, A., Elias, J. A., & McDonald, D. M. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63369-x · Cited by 125
“The induction of fenestrations is a well-known effect of VEGF on blood vessels.(25,26) Electron microscopy showed that newly formed vessels were associated with pericyte processes surrounded by basement membrane and fibroblast-like processes.”
BackgroundMu, X., Zhao, T., Xu, C., Shi, W., Geng, B., Shen, J., Zhang, C., Pan, J., Yang, J., Hu, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14485 · Cited by 124
“The well-known prototype of angiogenesis inducers is VEGF, which is a well-documented angiogenic mediator that can promote endothelial cells growth, maturation and survival [26].”
BackgroundChecco, J. W., Kreitler, D. F., Thomas, N. C., Belair, D. G., Rettko, N. J., Murphy, W. L., Forest, K. T., & Gellman, S. H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420380112 · Cited by 119
“A VDNKFNKEMHNAYAIEIALLPNLNDQQFHAFIWSLIDD-NH2 VDNKFNKEQHNARAIEAALDPNLNDQQFHAKIWSIIDD-NH2 VDNKFNKEQCNARAIEAALDPNLNDQQFHAKIWSIIDDC-NH2 VDNKFNKEXCNZRAIEUALDPNLNDQQFHUKIWZIIXDC-NH2 VDNKFNKEXCNZRAIEUALDPNLNDUQFHUKIWZIIXDC-NH2 VDNKFNKXCQZRFYEULHDPNLNEEQRNUKIQZIKXDC-NH2 VDNKFNKXCQNRFYEULHDPNLNEEQRNUKIQZIKXDC-NH2 VDNKFNKXCGZRI…”
BackgroundInfluentialEndothelial podosome rosettes regulate vascular branching in tumour angiogenesis
Seano, G., Chiaverina, G., Gagliardi, P. A., di Blasio, L., Puliafito, A., Bouvard, C., Sessa, R., Tarone, G., Sorokin, L., Helley, D., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3036 · Cited by 119
“(2) When the tumour produces VEGF, the VEGF induces upregulation of the α6 integrin subunit in ECs.”
BackgroundPérez, D. G., Suman, V. J., Fitch, T. R., AMATRUDA, T. T., Morton, R. F., Jilani, S. Z., Constantinou, C. L., Egner, J. R., Kottschade, L. A., & Markovic, S. N. (2008) · Cancer · doi:10.1002/cncr.23987 · Cited by 125
“Vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen, is the most potent, specific, and well-defined soluble mediator of angiogenesis.(2) VEGF appears to play a crucial role in the pathogenesis, growth, and metastatic progression of melanoma.”
BackgroundChemical generation of bispecific antibodies
Doppalapudi, V. R., Huang, J., Liu, D., Jin, P., Liu, B., Li, L., Desharnais, J., Hagen, C., Levin, N. J., Shields, M. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016478108 · Cited by 126
“VEGF plays a dominant role in tumor angiogenesis (18, 19) and its inhibition has been implemented clinically, mostly in combination with chemotherapy, to treat cancers of intestine, liver (20), brain (21), colon (22), kidney (23–25), breast (26), and lung (27, 28).”
BackgroundMolecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy
Foersch, S., Kießlich, R., Waldner, M., Delaney, P., Galle, P. R., Neurath, M., & Goetz, M. (2010) · Gut · doi:10.1136/gut.2009.202986 · Cited by 124
“5 For example, vascular endothelial growth factor (VEGF) plays an important role in angiogenesis of healthy and malignant tissue.(6) As a consequence of tissue hypoxia or gene mutation, the VEGF-A isoform, commonly referred to as VEGF, promotes the mobilisation, migration and proliferation of new blood vessels.”
BackgroundNanoparticles of Copper Stimulate Angiogenesis at Systemic and Molecular Level
Mroczek-Sosnowska, N., Sawosz, E., Vadalasetty, K. P., Łukasiewicz, M., Niemiec, J., Wierzbicki, M., Kutwin, M., Jaworski, S., & Chwalibóg, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16034838 · Cited by 124
“VEGF signaling [21].”
Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake
Arjaans, M., Oude Munnink, T. H., Oosting, S. F., Terwisscha van Scheltinga, A. G. T., Gietema, J. A., Garbacik, E. T., Timmer-Bosscha, H., Lub-de Hooge, M. N., Schröder, C. P., & de Vries, E. G. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3518 · Cited by 121
“Angiogenesis, the formation of new blood vessels, is one of the hallmarks of cancer and is therefore an anticancer drug target (1, 2).”
The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic
Ye, W. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.03.015 · Cited by 129
Le, Y.-Z. (2017) · Vision Research · doi:10.1016/j.visres.2017.05.005 · Cited by 136
Fahimipour, F., Rasoulianboroujeni, M., Dashtimoghadam, E., Khoshroo, K., Tahriri, M., Bastami, F., Lobner, D., & Tayebi, L. (2017) · Dental Materials · doi:10.1016/j.dental.2017.06.016 · Cited by 128
Structure and Functions of Blood Vessels and Vascular Niches in Bone
Ramasamy, S. K. (2017) · Stem Cells International · doi:10.1155/2017/5046953 · Cited by 139
“An important downstream target of HIF-1α is VEGF, a fundamental factor required for blood vessel formation in physiological and pathological conditions [45].”
BackgroundYtrehus, B., Ekman, S., Carlson, C. S., Teige, J., & Reinholt, F. P. (2004) · Bone · doi:10.1016/j.bone.2004.08.016 · Cited by 124
“VEGF is regarded as one of the most important of the angiogenic factors [14] and is also subscribed important roles in promoting cell functions of hypertrophic chondrocytes, osteoblasts, osteoclasts, and endothelial cells in the enchondral ossification process [8,15,22,33,34].”
BackgroundThe Molecular Basis of VEGFR-1 Signal Transduction Pathways in Primary Human Monocytes
Tchaikovski, V., Fellbrich, G., & Waltenberger, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.158022 · Cited by 116
Microvascular development: learning from pancreatic islets
Konstantinova, I., & Lammert, E. (2004) · BioEssays · doi:10.1002/bies.20105 · Cited by 119
“VEGF-A was first identified as vascular permeability factor, VPF, before it was re-discovered as amitogenic, chemo-attractant and fenestrating factor for vascular endothelial cells.((7,8))”
BackgroundJensen, L. D., Cao, Z., Nakamura, M., Yang, Y., Bräutigam, L., Andersson, P., Zhang, Y., Wahlberg, E., Länne, T., Hosaka, K., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.07.005 · Cited by 127
“VEGF is a key angiogenic factor during embryonic development and in pathological conditions, including tumor growth and ophthalmological disorders (Ferrara et al., 2003; Nagy et al., 2007).”
BackgroundYamazaki, Y., Matsunaga, Y., Tokunaga, Y., Obayashi, S., Saito, M., & Morita, T. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809071200 · Cited by 123
Riddell, J. R., Bshara, W., Moser, M. T., Spernyak, J. A., Foster, B. A., & Gollnick, S. O. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3674 · Cited by 119
“Prx1/TLR4 interaction regulates endothelial cell proliferation, migration, and differentiation VEGF mediates angiogenesis partly through its effects on endothelial cell proliferation, migration, and differentiation (32).”
García, J. R., Clark, A. Y., & García, A. J. (2015) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35626 · Cited by 124
Imaging-guided delivery of RNAi for anticancer treatment
Wang, J., Mi, P., Lin, G., Wáng, Y. X. J., Liu, G., & Chen, X. S. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.008 · Cited by 127
“Blocking the expression of VEGF is expected to inhibit angiogenesis and suppress tumor growth [71].”
BackgroundXiang, J., Li, J., He, J., Tang, X., Dou, C., Cao, Z., Yu, B., Zhao, C., Kang, F., Lü, Y., et al. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b00158 · Cited by 126
Overview of CD24 as a new molecular marker in ovarian cancer
Tarhriz, V., Bandehpour, M., Dastmalchi, S., Ouladsahebmadarek, E., Zarredar, H., & Eyvazi, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27581 · Cited by 122
Lin, S., Zhang, Q., Li, S., Zhang, T., Wang, L., Qin, X., Zhang, M., Shi, S., & Cai, X. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c00874 · Cited by 124
Vascular endothelial growth factor gene variability is associated with increased risk for AD
Del Bo, R., Scarlato, M., Ghezzi, S., Martinelli Boneschi, F., Fenoglio, C., Galbiati, S., Virgilio, R., Galimberti, D., Galimberti, G., Crimi, M., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20390 · Cited by 123
“We focused on vascular endothelial growth factor (VEGF), an angiogenic cytokine able to induce vascular endothelial cell proliferation, migration, and vasopermeability in many types of tissues.(6) VEGF has been implicated in neuronal survival, neuroprotection, regeneration, growth, differentiation, and axonal outgrowt…”
BackgroundSuhr, F., Brixius, K., de Marées, M., Bölck, B., Kleinöder, H., Achtzehn, S., Bloch, W., & Mester, J. (2007) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01160.2006 · Cited by 124
“VEGF. VEGF is a potent mitogen in endothelial cells ( 18 , 53).”
BackgroundSyed, D. N., Afaq, F., Kweon, M.-H., Hadi, N., Bhatia, N., Spiegelman, V. S., & Mukhtar, H. (2006) · Oncogene · doi:10.1038/sj.onc.1209829 · Cited by 130
“wide variety of tumor models, a phenomenon that has led to the clinical development of a variety of VEGF inhibitors (Ferrara et al., 2003).”
BackgroundYao, Y., Zhang, F., Wang, L., Zhang, G., Wang, Z., Chen, J., & Gao, X. (2009) · Journal of Biomedical Science · doi:10.1186/1423-0127-16-74 · Cited by 121
“In addition to its potent angiogenic function, VEGF can stimulate proliferation, delay senescence, suppress apoptosis and promote survival of various cells [22,23].”
BackgroundRETRACTED: Extracellular HSP27 mediates angiogenesis through Toll‐like receptor 3
Thuringer, D., Jégo, G., Wettstein, G., Terrier, O., Cronier, L., Yousfi, N., Hébrard, S., Bouchot, A., Hazoumé, A., Joly, A.-L., et al. (2013) · The FASEB Journal · doi:10.1096/fj.12-226977 · Cited by 122
“The binding of VEGF165 to VEGFR2 is enhanced by neuropilin-1 (NRP-1) expressed on endothelial cells, which acts as a coreceptor by forming a complex with VEGFR2 (14–16).”
BackgroundInfluentialRetractedZhang, S., Zhau, H. E., Osunkoya, A. O., Iqbal, S. A., Yang, X., Fan, S., Chen, Z., Wang, R., Marshall, F. F., Chung, L. W. K., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-9 · Cited by 127
“related receptor tyrosine kinases, VEGF-R1 and VEGFR2 [8].”
BackgroundInfluentialMoss, J., Gebara, E., Bushong, E. A., Sánchez-Pascual, I., O’Laoi, R., El M’Ghari, I., Kocher-Braissant, J., Ellisman, M. H., & Toni, N. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514652113 · Cited by 118
“Additionally, a related VEGF ligand and receptor combination, VEGF-C and VEGFR3, respectively (90), was recently shown to directly control RGL stem cell activation in the hippocampus without effecting other cell types (91).”
BackgroundCampbell, S. C., & Lane, B. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00049-9 · Cited by 122
Abdullaziz, M. A., Abdel‐Mohsen, H. T., Kerdawy, A. M. E., Ragab, F. A. F., Ali, M. M., Abu‐Bakr, S. M., Girgis, A. S., & Diwani, H. I. E. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.068 · Cited by 122
Vascularization strategies for skin tissue engineering
Amirsadeghi, A., Jafari, A., Eggermont, L. J., Hashemi, S., Bencherif, S. A., & Khorram, M. (2020) · Biomaterials Science · doi:10.1039/d0bm00266f · Cited by 136
Chen, W., Tang, T., Eastham-Anderson, J., Dunlap, D., Alicke, B., Nannini, M., Gould, S., Yauch, R., Modrusan, Z., DuPree, K. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017945108 · Cited by 119
“, hypoxia, cytokines, hormones, lipids, and Hh ligands) (17, 18).”
Increase of Both Angiogenesis and Bone Mass in Response to Exercise Depends on VEGF
Yao, Z., Lafage‐Proust, M., Plouët, J., Bloomfield, S. A., Alexandre, C., & Vico, L. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040517 · Cited by 131
“Among these factors, the endothelial cell-specific mitogen VEGF plays a key role for normal and abnormal angiogenesis.((21,22)) Alternative splicing of primary transcript from a single VEGF pre-mRNA produces at least five different isoforms of VEGF, three of them being more prevalent (VEGF 120, 164, and 188) in mice.”
BackgroundHuang, S., Wu, M., Shun, C., Wang, H., Hsieh, C., Kuo, M., & Lin, J. (2005) · Journal of Biomedical Science · doi:10.1007/s11373-004-8177-5 · Cited by 130
“Among them, vascular endothelial growth factor (VEGF) is one of the most potent tumor angiogenic factors, capable of promoting proliferation and migration of endothelial cells and increasing vascular permeability [ 7 ].”
BackgroundMichaud, S. É., Dussault, S., Groleau, J., Haddad, P., & Rivard, A. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.05.004 · Cited by 125
Regulation of Vascular Endothelial Growth Factor Signaling by miR-200b
Choi, Y.-C., Yoon, S., Jeong, Y., Yoon, J., & Baek, K. (2011) · Molecules and Cells · doi:10.1007/s10059-011-1042-2 · Cited by 128
“In tumor angiogenesis, one of the most important regulators is vascular endothelial growth factor (VEGF), which stimulates endothelial cell proliferation, migration, and survival through its receptors, Flt-1 (fms-like tyrosine kinase, or VEGFR-1) and KDR (kinase-insert domain containing receptor, or VEGFR-2) (Ferrara,…”
BackgroundHyperbaric Oxygen Attenuates Apoptosis and Decreases Inflammation in an Ischemic Wound Model
Zhang, Q., Chang, Q., Cox, R. A., Gong, X.-M., & Gould, L. J. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.53 · Cited by 133
“In these conditions, VEGF is strongly expressed by epidermal keratinocytes, leading to increased microvascular permeability and aberrant angiogenesis (Detmar et al., 1995; Ferrara et al., 2003).”
BackgroundPlatelet-rich plasma application in chondrogenesis
Mardani, M., Kabiri, A., Esfandiari, E., Esmaeili, A., Hashemibeni, B., & Pourazar, A. (2014) · Advanced Biomedical Research · doi:10.4103/2277-9175.135156 · Cited by 121
“,[22] 2003 Secreted by hypertrophic chondrocytes”
Nakanishi, Y., Akiyama, N., Tsukaguchi, T., Fujii, T., Sakata, K., Sase, H., Isobe, T., Morikami, K., Shindoh, H., Mio, T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0248 · Cited by 126
“3 1 3 10 HUVECs B as el in e D ay 1 D ay 2 D ay 3 D ay 4 D ay 7 10 0 −10 20 30 C ha ng e in d ia st ol ic bl oo d pr es su re ( m m H g) Administration Vehicle CH5183284 10 mg/kg/day CH5183284 30 mg/kg/day Mean ±SD (n = 4) D pY-KDR KDR TIK-cTIK-c-Yp (DMS-114) (SNU-16) (KMS11) MDA-MB453 (HUVEC) (NCI-H1703) (Kasumi-1) F…”
MethodInfluentialDecoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies
Liu, X., Zhang, J., Yi, T., Li, H., Tang, X., Liu, D., Wu, D., & Li, Y. (2025) · Biomarker Research · doi:10.1186/s40364-025-00779-x · Cited by 134
“This process, which includes steps such as endothelial cell activation, matrix degradation, cell invasion, proliferation, migration, formation of vascular lumen, and stabilization of new blood vessels, is tightly controlled by positive and negative regulators [35].”
Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability
Criscuoli, M. L., Nguyen, M., & Eliceiri, B. P. (2005) · Blood · doi:10.1182/blood-2004-06-2246 · Cited by 119
“VEGF and VEGF receptor2, are embryonic lethal.(4) Src-knockout mice, generated by Soriano and colleagues, which were first identified to have an osteoclast defect,(18) were later shown to have a defect in VEGF-mediated VP.”
BackgroundAntivascular endothelial growth factor therapy for neovascular age-related macular degeneration
Ciulla, T. A., & Rosenfeld, P. J. (2009) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32832d25b3 · Cited by 117
Pathogenesis of herpes stromal keratitis – A focus on corneal neovascularization
Giménez, F., Suryawanshi, A. S., & Rouse, B. T. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.07.002 · Cited by 125
“VEGF gradients play a key role guiding the sprouting of the blood vessels (Ferrara et al., 2003) and it is mediated by signalingmolecules of the Rho family of small GTPases, which include Rho, Cdc42 and RAC (Hoang et al., 2004).”
BackgroundThe Role of Vascular Endothelial Growth Factor in Metastatic Prostate Cancer to the Skeleton
Wanicek, E., Cossigny, D. A. F., & Quan, G. M. Y. (2013) · Prostate Cancer · doi:10.1155/2013/418340 · Cited by 121
“Ramucirumab is a human IgG1 monoclonal antibody which binds to the extracellular domain of VEGFR2 and blocks the VEGF-A to VEGFR-2 interaction and subsequent downstream signaling [84].”
BackgroundInfluentialTsao, A. S., He, D., Saigal, B., Liu, S., Lee, J. J., Bakkannagari, S., Ordóǹez, N. G., Hong, W. K., Wistuba, I. I., & Johnson, F. M. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0052 · Cited by 121
COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesis
Qin, J., Chen, X., Xie, X., Tsai, M.-J., & Tsai, S. Y. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914619107 · Cited by 118
“VEGF is a major mediator of angiogenesis, which transmits its signals primarily through binding to its receptor VEGFR-2, a receptor tyrosine kinase, on the surface of endothelial cells (7, 11).”
BackgroundPatterns of progression in patients with recurrent glioblastoma treated with bevacizumab
Pope, W. B., Xia, Q., Paton, V. E., Das, A., Hambleton, J., Kim, H. J., Huo, J., Brown, M. S., Goldin, J. G., & Cloughesy, T. F. (2011) · Neurology · doi:10.1212/wnl.0b013e31820a0a8a · Cited by 120
Management of Antiangiogenic Therapy-Induced Hypertension
de Jesús-González, N., Robinson, E., Moslehi, J. J., & Humphreys, B. D. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.196774 · Cited by 120
Schweighofer, B., Testori, J., Sturtzel, C., Sattler, S., Mayer, H., Wagner, O., Bilban, M., & Hofer, E. (2009) · Thrombosis and Haemostasis · doi:10.1160/th08-12-0830 · Cited by 114
“It is also a causative factor of pathologic angiogenesis associated with a multitude of diseases including cancer, chronic inflammatory diseases and retinopathy (1, 2).”
BackgroundTranscriptional regulation of vascular endothelial growth factor in cancer
LOUREIRO, R., & D'Amore, P. A. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.005 · Cited by 133
“VEGF, also known as VEGF-A or vascular permeability factor, is an endothelial mitogen and stimulator of angiogenesis and is a member of a family of growth factors that includes VEGF-B, -C, -D, -E and placental growth factor (reviewed in [2]).”
BackgroundSchiekofer, S., Galasso, G., Sato, K., Kraus, B. J., & Walsh, K. X. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000171994.89106.ca · Cited by 126
Immunolocalization of BMPs, BMP antagonists, receptors, and effectors during fracture repair
Yu, Y. Y., Lieu, S., Lu, C., Miclau, T., Marcucio, R., & Colnot, C. (2009) · Bone · doi:10.1016/j.bone.2009.11.005 · Cited by 119
Biomaterials Act as Enhancers of Growth Factors in Bone Regeneration
Chen, R., Wang, J., & Liu, C. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201603197 · Cited by 123
Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions
Lin, Z., Zhang, Q., & Luo, W. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.10.039 · Cited by 126
The universe of galectin-binding partners and their functions in health and disease
Troncoso, M. F., Elola, M. T., Blidner, A. G., Sarrias, L., Espelt, M. V., & Rabinovich, G. A. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105400 · Cited by 125
“VEGFRs, including VEGFR-1, VEGFR-2, and VEGFR-3, are key glycosylated receptors that mediate angiogenesis and lymphangiogenesis (239).”
BackgroundLin, C.-W., Wei, K., Liao, S., Huang, C.-Y., Sun, C., Wu, P.-J., Lin, Y.-J., Yang, H., & Ma, C.-C. M. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.08.080 · Cited by 121
Sunitinib malate for the treatment of solid tumours: a review of current clinical data
Motzer, R. J., Hoosen, S., Bello, C. L., & Christensen, J. G. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.5.553 · Cited by 119
“Dysregulation of endothelial VEGFR-1 and -2 and secretion of their cognate ligand VEGFA by tumour cells have been implicated in tumour-dependent angiogenesis [11,12], which is critical for continued growth and metastasis of most (if not all) solid tumours, including highly vascularised renal cell carcinoma (RCC).”
BackgroundShojaei, F., & Ferrara, N. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.09.001 · Cited by 131
Self-citationComplexity of tumor vasculature in clear cell renal cell carcinoma
Qian, C., Huang, D., Wondergem, B., & Teh, B. T. (2009) · Cancer · doi:10.1002/cncr.24238 · Cited by 120
Photodynamic Ablation of Lymphatic Vessels and Intralymphatic Cancer Cells Prevents Metastasis
Tammela, T., Saaristo, A., Holopainen, T., Ylä-Herttuala, S., Andersson, L. C., Virolainen, S., Immonen, I., & Alitalo, K. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001699 · Cited by 120
Laurie, S. A., Gauthier, I. C., Arnold, A., Shepherd, F. A., Ellis, P. M., Chen, E. X., Goss, G. D., Powers, J., Walsh, W., Tu, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4741 · Cited by 119
Ferreira, M., de Mendonça, R. J., Coutinho‐Netto, J., & Mulato, M. (2009) · Brazilian Journal of Physics · doi:10.1590/s0103-97332009000500010 · Cited by 119
“VEGF is specific for vascular endothelial cells and increases the vascular permeability [5,6].”
BackgroundPeptide-Based Functional Biomaterials for Soft-Tissue Repair
Hosoyama, K., Lazurko, C., Muñoz, M., McTiernan, C. D., & Alarcon, E. I. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00205 · Cited by 118
“It may also be interesting to explore the ability of these VEGF mimics to bind heparin as there is much literature regarding the propensity of different isoforms of VEGF to bind heparin and the necessity of this binding to promote endothelial cell growth and proliferation (Ferrara et al., 2003).”
Background
Metadata
- Authors
- Ferrara, N., Gerber, H.-P., & LeCouter, J.
- Affiliations
- Genentech (US)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature Medicine
- Published
- 2003-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 669-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2000292756
- Cited by
- 9,591
- References
- 144
- Citations by year
- 2026: 154 · 2025: 270 · 2024: 292 · 2023: 317 · 2022: 336 · 2021: 386 · 2020: 379 · 2019: 403 · 2018: 384 · 2017: 466 · 2016: 460 · 2015: 485 · 2014: 551 · 2013: 527 · 2012: 580
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vascular endothelial growth factor, VEGF receptors, VEGFR1, VEGFR2, receptor tyrosine kinase signaling, angiogenesis, pathological angiogenesis, tumor angiogenesis, intraocular neovascularization, VEGF inhibitors, age-related macular degeneration, vascular leakage, embryonic development
- MeSH terms
- Animals, Clinical Trials as Topic, Endothelium, Vascular, Growth Substances, Humans, Lymphokines, Neovascularization, Pathologic, Oxygen, Signal Transduction, Endothelial Growth Factors, Neovascularization, Physiologic, Protein Isoforms, Intercellular Signaling Peptides and Proteins, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.